Analyses / PFE
Large-cap pharma at $28.06 with a 5.4% dividend yield. Earnings and revenue are declining, and the payout ratio is above 100%.
A free account reveals PFE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Forward P/E of 20.6x is well below the trailing 39.8x, which suggests the market may expect earnings to normalize. Gross margin of 75.8% and operating margin of 15.0% show a high-margin base. Shares trade 57% of the way up the 52-week range with a 5.4% dividend yield. Insider transactions skew toward buying (77 buys vs 27 sells, about 3.5M shares bought vs 1.6M sold). Beta of 0.29 implies low sensitivity to broad market moves.
▼ Bear Case
Revenue fell 14.8% and EPS fell 37.1% year over year, so the trailing P/E of 39.8x reflects shrinking earnings. The payout ratio of 125.8% means the dividend exceeds reported earnings, which could pressure the payout if earnings do not recover. Quick ratio of 0.87 is below 1.0. Debt-to-equity and interest coverage are unavailable in the data, so balance sheet strain cannot be fully assessed. The stock is 2.6% above its 52-week low.
Valuation
MIXED VALUE — score 58/100
Forward multiples look reasonable, but trailing P/E is elevated because earnings are falling. Dividend yield is high but not covered by earnings.
Technical Levels
Support · $28.00 (Day low) · $23.62 (52-week low)
Resistance · $28.47 (Prior close) · $31.44 (52-week high)
RSI: Not available in provider data
Financial Health
Score 55/100. Liquidity is adequate on current ratio but thin on quick ratio. Payout exceeds earnings. Leverage cannot be fully assessed with current data.
Catalysts
| Quarterly dividend payment (headline cites Dec. 7) | Dec. 7 per headline | Supports income thesis if maintained |
| Next quarterly earnings report | Date not in provider data | High. Revenue trend and payout coverage are the key checks |
| China in vivo CAR-T licensing deal | Recent per headline | Low to medium. Pipeline optionality, financial size not disclosed in data |
Risk Flags
See PFE's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock PFE free →Recent News
- Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak.Yahoo
- S&P 500 Most Active Stocks on Nov. 18: AES Leads Volume, Freeport-McMoRan Drops 6.45%ChartMill
- Sector Update: Healthcare Stocks Decline in Afternoon TradingYahoo
- Pfizer leaps into 'in vivo' CAR-T with latest China dealYahoo
- Is Lilly Stock's Winning Streak Skill Or Luck?Yahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full PFE analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
PFE FAQ
Is PFE a buy right now?
Pfizer Inc.'s current read is a Value and income, recovery watch setup with medium confidence over a 1-3 months horizon. Valuation: MIXED VALUE. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is PFE overvalued?
MIXED VALUE (valuation score 58/100). Forward multiples look reasonable, but trailing P/E is elevated because earnings are falling. Dividend yield is high but not covered by earnings.
What are the risks of buying PFE?
Revenue fell 14.8% and EPS fell 37.1% year over year, so the trailing P/E of 39.8x reflects shrinking earnings. The payout ratio of 125.8% means the dividend exceeds reported earnings, which could pressure the payout if earnings do not recover. Quick ratio of 0.87 is below 1.0. Debt-to-equity and interest coverage are unavailable in the data, so balance sheet strain cannot be fully assessed. The stock is 2.6% above its 52-week low.